Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$15.87 - $23.12 $1.47 Million - $2.14 Million
-92,567 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $14,931 - $32,026
883 Added 0.96%
92,567 $1.69 Million
Q2 2019

Aug 14, 2019

BUY
$31.0 - $36.3 $320,137 - $374,870
10,327 Added 12.69%
91,684 $3.26 Million
Q1 2019

May 15, 2019

SELL
$31.58 - $46.35 $5.63 Million - $8.26 Million
-178,190 Reduced 68.65%
81,357 $2.73 Million
Q4 2018

Feb 13, 2019

BUY
$30.43 - $56.65 $35,329 - $65,770
1,161 Added 0.45%
259,547 $8.54 Million
Q3 2018

Nov 14, 2018

SELL
$46.46 - $68.49 $38,283 - $56,435
-824 Reduced 0.32%
258,386 $15.8 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $11.9 Million - $27 Million
258,175 Added 24944.44%
259,210 $12.6 Million
Q1 2018

May 14, 2018

BUY
$57.4 - $108.44 $59,409 - $112,235
1,035 New
1,035 $110,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Asset Management One Co., Ltd. Portfolio

Follow Asset Management One Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management One Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Asset Management One Co., Ltd. with notifications on news.